Fig. 3. When advanced stage patients were analyzed according to immunophenotype, the overall survival (A) and event-free survival rates (B) were not statistically different between B- and T-LBL (N=43).

Blood Res 2020;55:262~274 https://doi.org/10.5045/br.2020.2020220